Free Trial
→ One page of the SpaceX S-1 will move this stock overnight (From Behind the Markets) (Ad)tc pixel Free AMLX Stock Alerts

Amylyx Pharmaceuticals (AMLX) Financials

Amylyx Pharmaceuticals logo
$13.55 +0.54 (+4.15%)
Closing price 06/9/2026 04:00 PM Eastern
Extended Trading
$13.50 -0.05 (-0.35%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Amylyx Pharmaceuticals

Annual Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -88 -198 49 -302 -145
Consolidated Net Income / (Loss)		 -88 -198 49 -302 -145
Net Income / (Loss) Continuing Operations		 -88 -198 49 -302 -145
Total Pre-Tax Income 		-88 -198 54 -302 -145
Total Operating Income		 -83 -201 39 -315 -153
Total Gross Profit		 0.29 19 355 81 0.00
Total Revenue		 0.29 22 381 87 0.00
Operating Revenue		 0.29 22 381 87 0.00
Total Cost of Revenue		 0.00 2.99 25 5.95 0.00
Operating Cost of Revenue		 0.00 2.99 25 5.95 0.00
Total Operating Expenses		 83 221 317 396 153
Selling, General & Admin Expense		 39 127 188 114 63
Research & Development Expense		 44 93 128 140 90
Other Operating Expenses / (Income)		 - - 0.00 119 0.00
Restructuring Charge		 - - 0.00 23 0.00
Total Other Income / (Expense), net		 -5.24 3.74 15 13 8.60
Interest & Investment Income		 0.04 4.29 16 14 9.30
Other Income / (Expense), net		 -5.28 -0.55 -0.66 -1.21 -0.70
Income Tax Expense		 0.00 0.77 5.03 -0.39 0.05
Basic Earnings per Share		 ($13.35) ($3.39) $0.73 ($4.43) ($1.53)
Weighted Average Basic Shares Outstanding		 6.59M 58.50M 67.23M 68.14M 94.57M
Diluted Earnings per Share		 ($13.35) ($3.39) $0.70 ($4.43) ($1.53)
Weighted Average Diluted Shares Outstanding		 6.59M 58.50M 69.99M 68.14M 94.57M
Weighted Average Basic & Diluted Shares Outstanding		 - 66.72M 67.78M 88.60M 110.54M

Quarterly Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33 -41
Consolidated Net Income / (Loss)		 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33 -41
Net Income / (Loss) Continuing Operations		 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33 -41
Total Pre-Tax Income 		22 6.48 -119 -73 -73 -38 0.00 -41 -34 -33 0.00
Total Operating Income		 19 1.93 -122 -76 -76 -41 -38 -43 -36 -37 -44
Total Gross Profit		 97 99 83 -1.03 0.42 -0.67 0.00 0.00 0.00 - 0.00
Total Revenue		 103 108 89 -1.02 0.42 -0.67 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 5.22 9.36 5.95 0.01 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 79 97 205 75 76 40 38 43 36 37 44
Selling, General & Admin Expense		 49 52 58 22 18 17 16 16 16 15 16
Research & Development Expense		 30 45 37 23 57 23 22 27 20 21 28
Total Other Income / (Expense), net		 3.69 4.54 3.58 3.59 2.96 2.47 1.90 1.41 1.64 3.65 2.50
Interest & Investment Income		 4.18 4.37 4.33 4.07 3.10 2.32 2.23 1.96 1.82 3.29 2.57
Other Income / (Expense), net		 -0.49 0.17 -0.75 -0.48 -0.14 0.16 -0.34 -0.55 -0.18 0.36 -0.08
Income Tax Expense		 1.52 1.75 0.24 0.00 0.00 -0.64 0.00 0.00 0.00 0.05 0.00
Basic Earnings per Share		 $0.31 $0.07 ($1.75) ($1.07) ($1.07) ($0.54) ($0.42) ($0.46) ($0.37) ($0.28) ($0.37)
Weighted Average Basic Shares Outstanding		 67.41M 67.23M 67.85M 68.02M 68.09M 68.14M 85.70M 89.14M 93.33M 94.57M 110.56M
Diluted Earnings per Share		 $0.30 $0.07 ($1.75) ($1.07) ($1.07) ($0.54) ($0.42) ($0.46) ($0.37) ($0.28) ($0.37)
Weighted Average Diluted Shares Outstanding		 69.75M 69.99M 67.85M 68.02M 68.09M 68.14M 85.70M 89.14M 93.33M 94.57M 110.56M
Weighted Average Basic & Diluted Shares Outstanding		 67.52M 67.78M 68.01M 68.08M 68.55M 88.60M 89.14M 89.17M 109.82M 110.54M 111.19M

Annual Cash Flow Statements for Amylyx Pharmaceuticals

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 37 13 108 -92 149
Net Cash From Operating Activities		 -75 -180 12 -168 -123
Net Cash From Continuing Operating Activities		 -75 -180 12 -168 -123
Net Income / (Loss) Continuing Operations		 -88 -198 49 -302 -145
Consolidated Net Income / (Loss)		 -88 -198 49 -302 -145
Depreciation Expense		 0.05 0.49 1.09 0.90 0.53
Amortization Expense		 0.12 -2.06 -9.94 -9.86 -5.53
Non-Cash Adjustments To Reconcile Net Income		 8.37 23 37 191 29
Changes in Operating Assets and Liabilities, net		 4.60 -3.28 -66 -48 -2.81
Net Cash From Investing Activities		 -46 -239 92 76 14
Net Cash From Continuing Investing Activities		 -46 -239 92 76 14
Purchase of Property, Plant & Equipment		 -0.35 -2.53 -1.24 -0.16 -0.14
Acquisitions		 - - 0.00 -36 0.00
Purchase of Investments		 -49 -416 -301 -232 -232
Sale and/or Maturity of Investments		 3.00 179 394 344 246
Net Cash From Financing Activities		 159 432 3.54 0.35 257
Net Cash From Continuing Financing Activities		 159 432 3.54 0.35 257
Issuance of Debt		 12 0.00 - 0.00 256
Other Financing Activities, net		 12 231 3.54 0.35 0.72
Effect of Exchange Rate Changes		 0.01 -0.07 0.16 -0.44 1.07

Quarterly Cash Flow Statements for Amylyx Pharmaceuticals

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -113 35 0.35 -96 -2.44 5.56 -18 -1.68 167 1.48 2.49
Net Cash From Operating Activities		 -5.17 14 -0.49 -67 -42 -59 -40 -25 -30 -28 -37
Net Cash From Continuing Operating Activities		 -5.17 14 -0.49 -67 -42 -59 -40 -25 -30 -28 -37
Net Income / (Loss) Continuing Operations		 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33 -41
Consolidated Net Income / (Loss)		 21 4.73 -119 -73 -73 -38 -36 -41 -34 -33 -41
Depreciation Expense		 0.30 0.30 0.32 0.21 0.22 0.16 0.16 0.14 0.12 0.11 0.10
Amortization Expense		 -2.48 -2.57 -2.58 -3.18 -2.31 -1.79 -1.70 -1.52 -1.24 -1.06 -0.61
Non-Cash Adjustments To Reconcile Net Income		 11 8.20 121 18 44 5.42 7.35 8.20 7.41 6.25 10
Changes in Operating Assets and Liabilities, net		 -35 2.89 -0.31 -9.18 -11 -25 -9.72 9.38 -2.27 -0.20 -5.56
Net Cash From Investing Activities		 -108 21 0.82 -29 39 65 -44 23 5.24 29 36
Net Cash From Continuing Investing Activities		 -108 21 0.82 -29 39 65 -44 23 5.24 29 36
Purchase of Property, Plant & Equipment		 -0.36 -0.36 -0.07 -0.09 0.02 -0.02 -0.01 -0.02 -0.02 -0.09 0.00
Purchase of Investments		 -164 -127 -73 -159 - - -104 -39 -59 -30 -20
Sale and/or Maturity of Investments		 57 148 74 130 75 65 60 62 64 60 60
Other Investing Activities, net		 - - - - - - 0.00 - - - -4.00
Net Cash From Financing Activities		 0.89 0.23 0.13 0.03 0.08 0.11 66 -0.03 192 -0.21 3.22
Net Cash From Continuing Financing Activities		 0.89 0.23 0.13 0.03 0.08 0.11 66 -0.03 192 -0.21 3.22
Issuance of Debt		 - - 0.00 - - - 66 - 191 -0.38 0.00
Other Financing Activities, net		 0.89 0.23 0.13 0.03 0.08 0.11 0.09 -0.03 0.50 0.17 3.22
Effect of Exchange Rate Changes		 -0.13 0.24 -0.11 -0.04 0.24 -0.53 0.20 0.61 0.15 0.12 -0.11

Annual Balance Sheets for Amylyx Pharmaceuticals

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 106 391 517 194 333
Total Current Assets		 105 382 465 189 324
Cash & Equivalents		 50 63 170 77 227
Short-Term Investments		 46 284 201 99 90
Prepaid Expenses		 5.39 10 15 12 6.69
Plant, Property, & Equipment, net		 0.47 2.61 2.69 0.96 0.31
Total Noncurrent Assets		 0.19 6.71 50 3.22 8.66
Other Noncurrent Operating Assets		 0.19 6.71 50 3.22 8.66
Total Liabilities & Shareholders' Equity		 106 391 517 194 333
Total Liabilities		 17 51 84 29 27
Total Current Liabilities		 17 47 82 28 23
Accounts Payable		 4.37 6.26 22 2.94 3.52
Accrued Expenses		 13 38 58 24 18
Other Current Liabilities		 0.00 2.04 2.26 1.52 1.26
Total Noncurrent Liabilities		 0.04 4.24 1.98 0.46 4.70
Other Noncurrent Operating Liabilities		 0.00 4.24 1.98 0.46 4.70
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -151 341 433 165 305
Total Preferred & Common Equity		 -151 341 433 165 305
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -151 341 433 165 305
Common Stock		 4.67 695 738 772 1,056
Retained Earnings		 -156 -354 -305 -607 -751
Accumulated Other Comprehensive Income / (Loss)		 0.01 -0.09 0.20 -0.09 0.40

Quarterly Balance Sheets for Amylyx Pharmaceuticals

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 181 408 454 467 417 332 251 220 195 363 294
Total Current Assets		 172 389 427 434 411 327 245 216 187 353 285
Cash & Equivalents		 108 115 248 135 171 75 72 60 58 225 229
Short-Term Investments		 55 231 110 220 203 235 163 144 123 119 51
Prepaid Expenses		 8.34 13 12 17 17 13 9.14 12 5.96 9.26 5.26
Plant, Property, & Equipment, net		 2.12 2.56 2.64 2.76 2.46 1.47 1.25 0.82 0.45 0.40 0.21
Total Noncurrent Assets		 7.13 16 24 30 4.46 3.97 4.20 2.72 7.26 8.96 8.37
Other Noncurrent Operating Assets		 7.13 16 24 30 4.46 3.97 4.20 2.72 7.26 8.96 8.37
Total Liabilities & Shareholders' Equity		 181 408 454 467 417 332 251 220 195 363 294
Total Liabilities		 37 55 67 48 93 71 55 18 27 31 20
Total Current Liabilities		 33 52 64 46 92 70 54 18 21 26 16
Accounts Payable		 7.05 11 25 6.37 21 4.96 1.49 4.81 3.29 5.34 3.53
Accrued Expenses		 24 39 37 37 68 63 50 12 17 19 11
Other Current Liabilities		 1.99 2.09 2.15 2.20 2.31 2.37 1.97 1.06 0.67 0.98 1.16
Total Noncurrent Liabilities		 4.77 3.69 3.14 2.57 1.38 0.77 0.60 0.33 5.30 4.95 4.48
Other Noncurrent Operating Liabilities		 4.77 3.69 3.14 2.57 1.38 0.77 0.60 0.33 5.30 4.95 4.48
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 144 353 386 418 324 261 196 201 168 332 273
Total Preferred & Common Equity		 144 353 386 418 324 261 196 201 168 332 273
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 144 353 386 418 324 261 196 201 168 332 273
Common Stock		 456 705 717 728 748 758 765 844 851 1,050 1,066
Retained Earnings		 -312 -353 -331 -310 -424 -496 -569 -643 -684 -718 -793
Accumulated Other Comprehensive Income / (Loss)		 -0.73 0.03 -0.07 -0.15 -0.08 -0.10 0.64 0.00 0.55 0.82 0.24

Annual Metrics And Ratios for Amylyx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 - - - 109,819,569.00
DEI Adjusted Shares Outstanding		 0.00 - - - 109,819,569.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 - - - -1.32
Growth Metrics		 - - - - -
Profitability Metrics		 - - - - -
Net Operating Profit after Tax (NOPAT)		 -58 -141 35 -220 -107
Return On Investment Capital (ROIC_SIMPLE)		 - - 8.12% -133.71% -35.15%
Earnings before Interest and Taxes (EBIT)		 -88 -202 38 -316 -154
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -88 -203 29 -325 -159
Valuation Ratios		 - - - - -
Leverage & Solvency		 - - - - -
Liquidity Ratios		 - - - - -
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -143 -33 -147 -105
Efficiency Ratios		 - - - - -
Capital & Investment Metrics		 - - - - -
Invested Capital		 -7.94 -6.34 62 -12 -14
Increase / (Decrease) in Invested Capital		 0.00 1.60 68 -74 -2.46
Book Value per Share		 ($22.95) $5.14 $6.42 $2.40 $2.78
Tangible Book Value per Share		 ($22.95) $5.14 $6.42 $2.40 $2.78
Total Capital		 88 341 433 165 305
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -96 -347 -371 -177 -317
Capital Expenditures (CapEx)		 0.35 2.53 1.24 0.16 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.56 -11 11 -15 -16
Debt-free Net Working Capital (DFNWC)		 88 336 383 161 301
Net Working Capital (NWC)		 88 336 383 161 301
Net Nonoperating Expense (NNE)		 30 57 -14 81 37
Net Nonoperating Obligations (NNO)		 -96 -347 -371 -177 -319
Total Depreciation and Amortization (D&A)		 0.17 -1.57 -8.85 -8.95 -5.00
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.39) $0.73 ($4.43) ($1.53)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 58.50M 67.23M 68.14M 94.57M
Adjusted Diluted Earnings per Share		 $0.00 ($3.39) $0.70 ($4.43) ($1.53)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 58.50M 69.99M 68.14M 94.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 66.72M 67.78M 88.60M 110.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -58 -141 35 -204 -107
Debt Service Ratios		 - - - - -
Payout Ratios		 - - - - -

Quarterly Metrics And Ratios for Amylyx Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 88,602,468.00 89,141,087.00 89,167,432.00 109,819,569.00 110,536,944.00
DEI Adjusted Shares Outstanding		 - - - - - - 88,602,468.00 89,141,087.00 89,167,432.00 109,819,569.00 110,536,944.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.41 -0.46 -0.39 -0.30 -0.37
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 29,666.09% 395.54% 24.10% -101.04% -99.59% -100.61% -100.00% 100.00% -100.00% - 0.00%
EBITDA Growth		 129.50% 99.65% -2,395.89% -532.94% -585.21% -25,278.31% 68.29% 43.84% 52.07% - -11.79%
EBIT Growth		 133.46% 104.65% -5,207.86% -481.56% -515.76% -2,023.85% 68.96% 43.46% 52.23% - -14.99%
NOPAT Growth		 145.59% 104.53% -3,614.16% -387.49% -403.48% -2,114.18% 69.05% 43.82% 52.38% - -15.81%
Net Income Growth		 138.87% 111.08% -7,652.00% -429.35% -447.98% -893.62% 69.77% 42.99% 52.70% - -14.97%
EPS Growth		 132.61% 111.48% -8,850.00% -445.16% -456.67% -871.43% 76.00% 57.01% 65.42% - 11.90%
Operating Cash Flow Growth		 88.00% 127.27% 90.36% -873.38% -704.22% -535.45% -8,043.97% 62.08% 26.95% - 7.39%
Free Cash Flow Firm Growth		 -227.05% -104.18% -26.03% 199.12% 175.36% 167.69% -145.00% -370.98% -205.83% - 63.27%
Invested Capital Growth		 441.26% 1,079.33% -800.56% -266.74% -160.28% -118.91% 94.57% 73.30% 68.60% - -149.23%
Revenue Q/Q Growth		 4.56% 5.61% -18.26% -101.15% 140.66% -259.86% 100.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 -12.85% -101.03% -75,287.95% 36.28% 2.32% 45.91% 5.80% -12.85% 16.65% - -19.29%
EBIT Q/Q Growth		 -9.38% -88.45% -5,937.39% 37.52% 1.26% 46.58% 5.83% -13.81% 16.58% - -21.00%
NOPAT Q/Q Growth		 -6.04% -91.90% -6,150.87% 37.54% 0.82% 46.27% 7.01% -13.37% 15.94% - -19.60%
Net Income Q/Q Growth		 -5.35% -77.36% -2,610.95% 38.80% -0.01% 48.36% 4.37% -15.42% 17.03% - -25.11%
EPS Q/Q Growth		 -3.23% -76.67% -2,600.00% 38.86% 0.00% 49.53% 22.22% -9.52% 19.57% - -32.14%
Operating Cash Flow Q/Q Growth		 -160.04% 362.16% -103.61% -13,515.54% 37.56% -41.95% 32.51% 36.60% -20.28% - -32.18%
Free Cash Flow Firm Q/Q Growth		 -164.14% -3.92% 55.73% 181.56% 100.83% -6.66% -260.24% 9.79% 21.57% - -4.00%
Invested Capital Q/Q Growth		 117.80% -2.03% -178.71% 0.72% 21.26% 69.27% 77.41% -388.46% 7.38% - 43.63%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 94.92% 91.37% 93.29% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 15.63% -0.15% -141.18% 0.00% -18,722.60% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 18.23% 1.78% -137.78% 0.00% -18,187.74% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 17.75% 1.94% -138.62% 0.00% -18,221.63% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 20.35% 4.36% -134.01% 0.00% -17,476.92% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 93.23% 73.05% 100.20% 100.00% 100.00% 98.34% 100.00% 100.00% 100.00% - 0.00%
Interest Burden Percent		 122.92% 307.65% 96.48% 94.70% 95.91% 94.28% 94.15% 95.48% 94.97% - 0.00%
Effective Tax Rate		 6.77% 26.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 223.27% 17.80% 0.00% 0.00% -198,826.27% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 221.94% 16.88% 0.00% 0.00% -198,819.57% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -204.27% -15.66% 0.00% 0.00% 190,679.53% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 19.00% 2.14% -21.00% -51.22% -8,146.74% 0.00% -83.24% -87.42% -56.52% - -63.26%
Cash Return on Invested Capital (CROIC)		 -133.23% -53.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 16.12% 1.63% -133.68% 0.00% -9,982.69% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 18.47% 3.66% -129.24% 0.00% -9,574.70% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 19.00% 2.14% -21.00% -51.22% -8,146.74% 0.00% -83.24% -87.42% -56.52% - -63.26%
Return on Equity Simple (ROE_SIMPLE)		 0.44% 0.00% -21.91% -63.48% -132.24% 0.00% -108.66% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 17 1.41 -85 -53 -53 -28 -26 -30 -25 -26 -31
NOPAT Margin		 16.99% 1.30% -96.44% 0.00% -12,731.42% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 1.33% 0.92% -9.26% -5.79% -6.70% -3.32% -3.27% -4.66% -3.17% - -4.40%
Return On Investment Capital (ROIC_SIMPLE)		 - 0.33% - - - -17.27% -13.14% -17.87% -7.60% -8.39% -11.22%
Cost of Revenue to Revenue		 5.08% 8.63% 6.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 47.44% 48.17% 65.16% 0.00% 4,285.58% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 29.25% 41.41% 41.30% 0.00% 13,807.69% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 76.69% 89.59% 231.07% 0.00% 18,287.74% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 18 2.11 -123 -77 -76 -40 -38 -43 -36 -36 -44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 16 -0.17 -125 -80 -78 -42 -40 -45 -37 -37 -44
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.95 2.29 0.59 0.49 1.12 1.57 1.56 3.40 3.65 - 5.62
Price to Tangible Book Value (P/TBV)		 2.95 2.29 0.59 0.49 1.12 1.57 1.56 3.40 3.65 - 5.62
Price to Revenue (P/Rev)		 4.19 2.61 0.48 0.43 1.12 2.97 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 671.94 20.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.15% 4.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 13.87 10.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 2.99 1.63 0.00 0.00 0.00 0.95 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 21.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 16.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 17.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 52.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -0.92 -0.93 -1.06 -1.03 -0.96 -0.92 -1.10 -1.14 -1.10 - -1.02
Leverage Ratio		 1.15 1.17 1.22 1.21 1.17 1.19 1.21 1.23 1.16 - 1.08
Compound Leverage Factor		 1.42 3.61 1.18 1.15 1.12 1.12 1.14 1.17 1.10 - 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 16.19 7.91 0.71 0.07 -0.05 1.76 6.72 8.19 21.63 - 41.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.52 5.66 4.48 4.66 4.55 6.67 12.05 8.72 13.70 - 17.85
Quick Ratio		 8.43 5.01 4.30 4.48 4.38 6.23 11.40 8.45 13.34 - 17.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -64 -67 -30 24 49 45 -73 -66 -51 -23 -27
Operating Cash Flow to CapEx		 -1,447.90% 3,806.46% -729.85% -74,808.99% 0.00% -295,040.00% -362,036.36% -148,517.65% -126,533.33% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.91 0.84 0.96 0.76 0.55 0.25 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 19.95 13.76 21.00 15.91 12.64 4.31 0.00 0.00 0.00 - 0.00
Inventory Turnover		 1.15 1.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 120.61 143.77 158.63 145.38 97.92 47.91 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 2.82 1.80 1.62 1.38 3.90 0.48 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 18.29 26.53 17.38 22.95 28.87 84.59 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 318.01 344.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 129.60 203.14 225.29 263.56 93.65 766.42 599,124.69 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 206.70 168.38 -207.91 -240.61 -64.78 -681.83 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 63 62 -49 -49 -38 -12 -2.65 -13 -12 -14 -6.61
Invested Capital Turnover		 13.14 13.66 -19.01 -30.78 15.62 3.47 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 82 68 -56 -78 -102 -74 46 36 26 -2.46 -3.96
Enterprise Value (EV)		 879 622 -182 -181 -14 83 110 391 868 - 1,257
Market Capitalization		 1,234 994 192 129 221 259 314 571 1,212 - 1,536
Book Value per Share		 $6.21 $6.42 $4.78 $3.84 $2.88 $2.40 $2.27 $1.88 $3.72 $2.78 $2.47
Tangible Book Value per Share		 $6.21 $6.42 $4.78 $3.84 $2.88 $2.40 $2.27 $1.88 $3.72 $2.78 $2.47
Total Capital		 418 433 324 261 196 165 201 168 332 305 273
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -355 -371 -373 -310 -234 -177 -204 -181 -344 -317 -280
Capital Expenditures (CapEx)		 0.36 0.36 0.07 0.09 -0.02 0.02 0.01 0.02 0.02 0.09 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 33 11 -54 -53 -43 -15 -5.86 -15 -16 -16 -11
Debt-free Net Working Capital (DFNWC)		 388 383 319 257 191 161 198 165 328 301 269
Net Working Capital (NWC)		 388 383 319 257 191 161 198 165 328 301 269
Net Nonoperating Expense (NNE)		 -3.44 -3.32 33 19 20 9.09 9.44 11 9.17 7.38 11
Net Nonoperating Obligations (NNO)		 -355 -371 -373 -310 -234 -177 -204 -181 -344 -319 -280
Total Depreciation and Amortization (D&A)		 -2.18 -2.27 -2.27 -2.97 -2.08 -1.63 -1.55 -1.38 -1.12 -0.95 -0.51
Debt-free, Cash-free Net Working Capital to Revenue		 11.37% 2.96% -13.67% -17.80% -21.91% -17.71% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 132.04% 100.48% 80.12% 85.90% 97.39% 184.30% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 132.04% 100.48% 80.12% 85.90% 97.39% 184.30% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.31 $0.07 ($1.75) ($1.07) ($1.07) ($0.54) ($0.42) ($0.46) ($0.37) ($0.28) ($0.37)
Adjusted Weighted Average Basic Shares Outstanding		 67.41M 67.23M 67.85M 68.02M 68.09M 68.14M 85.70M 89.14M 93.33M 94.57M 110.56M
Adjusted Diluted Earnings per Share		 $0.30 $0.07 ($1.75) ($1.07) ($1.07) ($0.54) ($0.42) ($0.46) ($0.37) ($0.28) ($0.37)
Adjusted Weighted Average Diluted Shares Outstanding		 69.75M 69.99M 67.85M 68.02M 68.09M 68.14M 85.70M 89.14M 93.33M 94.57M 110.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 67.52M 67.78M 68.01M 68.08M 68.55M 88.60M 89.14M 89.17M 109.82M 110.54M 111.19M
Normalized Net Operating Profit after Tax (NOPAT)		 17 1.41 -85 -37 -53 -28 -26 -30 -25 -26 -31
Normalized NOPAT Margin		 16.99% 1.30% -96.44% 0.00% -12,731.42% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 21.82% 5.97% -133.74% 0.00% -17,476.92% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, investor-focused summary of Amylyx Pharmaceuticals (AMLX) using the latest quarterly data you provided, focusing on liquidity, financing activity, and profitability trends over the last four years.

  • Significant cash inflows from the sale/maturity of investments across multiple quarters, notably about $60M in Q4 2025, $64M in Q3 2025, and roughly $65M in Q4 2024 (with a ~ $74M item in Q3 2024), which bolster AMLX’s liquidity runway.
  • In Q3 2025, AMLX issued debt that added roughly $191M of cash, providing a meaningful near-term liquidity cushion.
  • Equity financing in 2025 helped strengthen the balance sheet, with Q2 2025 common stock issuance lifting Total Common Equity to approximately $851M.
  • Net financing activities in Q3 2025 delivered a substantial cash inflow (about $191.6M) from continuing financing activities, supporting liquidity.
  • Cash on hand climbed to around $225M by Q3 2025, signaling improved liquidity, though cash generation from operations remains negative.
  • In Q2 2025, AMLX reported a liquidity mix of about $58M in cash and $123M in short-term investments (roughly $181M total), indicating a sizable liquidity cushion.
  • Operating revenue remains effectively zero across many quarters, underscoring that AMLX remains in a pre-revenue phase and relies on external funding for cash needs.
  • Persistent net losses in 2025: Q4 net income about -$33.0M; Q3 about -$34.4M; Q2 about -$41.4M; Q1 about -$35.9M, reflecting ongoing profitability challenges.
  • Operating cash flow from continuing operations was negative in 2025 (roughly -$25M to -$30M per quarter), indicating continued cash burn from operations.
  • High and rising research and development (R&D) and SG&A costs relative to near-term revenue contribute to ongoing losses (e.g., Q4 2025 SGA = $15.39M, RD = $21.21M; Total Operating Expenses = $36.60M).
06/10/26 04:51 AM ETAI Generated. May Contain Errors.

Amylyx Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Amylyx Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Amylyx Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$144.74 million in 2025, rising from -$87.93 million in 2021. The previous period was -$301.74 million in 2024. View Amylyx Pharmaceuticals' forecast to see where analysts expect Amylyx Pharmaceuticals to go next.

Amylyx Pharmaceuticals' total operating income in 2025 was -$153.29 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $153.29 million

Over the last 4 years, Amylyx Pharmaceuticals' total revenue changed from $285 thousand in 2021 to $0.00 in 2025, a change of -100.0%.

Amylyx Pharmaceuticals' total liabilities were at $27.39 million at the end of 2025, a 5.1% decrease from 2024, and a 57.1% increase since 2021.

In the past 4 years, Amylyx Pharmaceuticals' cash and equivalents has ranged from $50.19 million in 2021 to $226.65 million in 2025, and is currently $226.65 million as of their latest financial filing in 2025.

Over the last 4 years, Amylyx Pharmaceuticals' book value per share changed from -22.95 in 2021 to 2.78 in 2025, a change of -112.1%.


Related Companies

Financial statements for NASDAQ:AMLX last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...
The Oxford Club | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel
Trump Is Eyeing the Biggest Monetary Shift Since Nixon
On August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...
Americas Gold Company | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Tesla. SolarCity. Twitter. This $4 stock is next.
Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel